查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080141

全球雙特異性抗體市場：按分子形式、技術平台、作用機制、藥物、適應症、給藥途徑和分銷管道分類－市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Bispecific Antibodies Market: By Molecule Format, Technology Platform, Mechanism of Action, Drug, Indication, Route of Administration, Distribution Channel - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球雙特異性抗體市場持續強勁且永續地擴張，反映出其在生物製藥和腫瘤學領域日益成長的重要性。預計到2025年，該市場規模將達到約144億美元，凸顯了雙特異性抗體療法在關鍵醫療系統中日益廣泛的商業性應用。這一成長得益於抗體工程技術的持續創新、臨床應用範圍的不斷擴大，以及對更具靶向性和有效性的療法（尤其是在未滿足需求較高的領域）日益成長的需求。

在2026年至2035年的預測期內，市場預計將呈現顯著上升趨勢，到2035年達到約559億美元。這一成長意味著約14.7%的複合年成長率，顯示市場將呈現穩定強勁的長期成長，而非短期波動。這一成長軌跡反映了雙特異性抗體從小眾治療領域轉變為現代免疫療法和精準醫療方法的主流組成部分。

顯著的市場趨勢

目前，全球雙特異性抗體市場集中在少數幾家領先的生物製藥公司手中，這些公司共同推動創新、臨床應用和商業性成長。這些關鍵企業透過早期對雙特異性平台的投資，建立了強大的競爭優勢。

羅氏佔雙特異性抗體市場約45%的佔有率，是該市場最主要的參與者。其領先地位得益於Hemlibra和Vavismo等重磅產品。 Hemlibra預計在2025年將創造約60億美元的銷售額，而Vavismo預計同期將貢獻約50億美元的銷售額。艾伯維也正憑藉其專注於腫瘤領域的產品組合和策略合作關係，迅速崛起為雙特異性抗體領域的主要競爭對手。其治療藥物EPKINLY（epcolitamab）預計在2025年前三個季度將創造約3.33億美元的銷售額。

自2014年安進公司開發出首個獲得FDA批准的基於Blinatumomab的雙特異性抗體療法以來，該公司一直是該領域的先驅。 2024年，該公司利用其專有的BiTE平台開發的小細胞肺癌治療藥物Imdelltra（tarlatamab）獲得批准，進一步鞏固了其市場地位。強生公司憑藉其不斷成長的血液疾病業務在市場上扮演著重要角色，該業務包括Tecvayli（teclistamagab）和Blincyto等療法。

Genmab持續引領雙特異性抗體生態系的重大創新，這主要得益於其專有的DuoBody平台。該平台能夠開發高度柔軟性且高效的抗體結構，包括適用於皮下注射的抗體結構。

主要成長促進因素

全球雙特異性抗體市場正經歷快速且永續的發展，這主要得益於一系列獲批產品的上市，這些產品展現出強勁且不斷成長的市場需求。核准數量的增加反映了全球監管機構對雙特異性抗體平台的安全性、有效性和治療價值日益增強的信心。隨著多個疾病領域臨床證據的不斷積累，監管機構正逐步加快評估和核准流程，從而推動這些先進生物製藥在全球範圍內的廣泛應用。

新機會的趨勢

雙特異性抗體市場臨床研發管線的發展趨勢，為我們深入了解不斷變化的治療重點提供了重要訊息，並凸顯了市場持續成長的巨大機會。臨床研發計畫的分佈反映了創新最集中的領域以及生物製藥公司最關注的疾病領域。隨著這些領域的日趨成熟，研發管線正日益呈現出從早期實驗到後期檢驗的系統性進展，這表明市場正朝著更具商業性可行性和臨床驗證的療法方向發展。

最佳化障礙

由於白血病和淋巴瘤的疾病機制複雜，且長期治療效果仍有許多局限性，因此，在雙特異性抗體市場，這兩种骨髓惡性腫瘤仍是重要的臨床挑戰。這些惡性腫瘤的特徵是復發率高，尤其是在完成第一線治療後，這使得疾病管理更加複雜，並降低了患者的整體存活率。即使患者對第一線治療反應良好，疾病復發仍然很常見，因此，人們仍然需要更持久有效的治療方案。

目錄

第1章摘要整理：全球雙特異性抗體市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 主要調查受訪者組成：按地區分類
  • 本研究的前提
  • 市場規模估算
  • 數據三角測量

第3章：全球雙特異性抗體市場概覽

  • 產業價值鏈分析
  • 產業展望
    • 全球雙特異性抗體和免疫腫瘤治療產業概覽
    • 血液腫瘤和固體癌領域的核准和研發管線擴展
    • 生產製造的複雜性、對合約研發產量機構（CDMO）的依賴、市場進入/報銷趨勢
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 分子形式的價格趨勢分析

第4章：全球雙特異性抗體市場分析

  • 競爭對手儀表板
    • 市場集中度
    • 企業市場占有率分析，2025 年
    • 競爭對手分析與基準測試

第5章：全球雙特異性抗體市場分析

  • 市場動態和趨勢
    • 成長促進因素
    • 市場阻礙因素
    • 市場機遇
    • 主要趨勢
  • 市場規模及預測（2020-2035 年）
    • 分子形式
      • 關鍵見解
        • 親愛的IgG
          • 全長IgG
          • 附加 IgG
        • 基於片段的
          • scFv（單鏈可變片段）
          • Fab（抗原結合片段）
        • 融合類型/多特異性
    • 透過技術平台
      • 關鍵見解
        • BiTE
        • CrossMAb
        • DART
        • Knob-into-Hole
        • 其他專有技術
    • 透過作用機制
      • 關鍵見解
        • 免疫細胞銜接器
        • 有效載荷交付
        • 雙訊號抑制
    • 藥物
      • 關鍵見解
        • Blinatumomab
        • 塔拉塔單抗
        • 卡妥昔單抗
        • 其他
    • 適應症
      • 關鍵見解
        • 血癌
        • 固體癌
        • 自體免疫/發炎性疾病
        • 眼科疾病
        • 其他
    • 透過行政途徑
      • 關鍵見解
        • 靜脈注射
        • 皮下注射
    • 透過分銷管道
      • 關鍵見解
        • 醫院藥房
        • 零售藥房
        • 網路藥房
    • 最終用戶
      • 關鍵見解
        • 醫院
        • 專業醫療機構及癌症中心
        • 其他
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 亞太其他地區
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • 阿拉伯聯合大公國（阿拉伯聯合大公國）
          • 其他中東和非洲
        • 南美洲
          • 阿根廷
          • 巴西
          • 南美洲其他地區

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

  • Akeso, Inc
  • Amgen
  • Roche
  • Genentech
  • Janssen
  • Taisho Pharmaceutical
  • Immunocore
  • 其他主要公司

第12章附錄

簡介目錄
Product Code: AA06261837

The global bispecific antibodies market is undergoing strong and sustained expansion, reflecting its growing importance within the broader biopharmaceutical and oncology landscapes. In 2025, the market is estimated to be valued at approximately USD 14.4 billion, highlighting the increasing commercial adoption of bispecific antibody therapies across major healthcare systems. This growth is being fueled by continuous innovation in antibody engineering, expanding clinical applications, and rising demand for more targeted and effective treatment options, particularly in areas of high unmet medical need.

Over the forecast period from 2026 to 2035, the market is projected to experience significant upward momentum, reaching an estimated value of around USD 55.9 billion by 2035. This expansion corresponds to a compound annual growth rate (CAGR) of approximately 14.7%, indicating steady and robust long-term growth rather than short-term volatility. The trajectory reflects the transition of bispecific antibodies from a niche therapeutic class into a mainstream component of modern immunotherapy and precision medicine approaches.

Noteworthy Market Developments

The global bispecific antibodies market is currently concentrated among a small group of dominant biopharmaceutical companies that collectively shape innovation, clinical adoption, and commercial growth. These leading players have established strong competitive positions through early investment in bispecific platforms.

Roche stands as the most dominant force in the bispecific antibodies market, commanding approximately 45% market share. The company's leadership is anchored by blockbuster products such as Hemlibra, which generated around USD 6 billion in sales in 2025, and Vabysmo, which contributed approximately USD 5 billion during the same period. AbbVie has also emerged as a key competitor in the bispecific landscape, largely through its oncology-focused portfolio and strategic partnerships. Its therapy EPKINLY (epcoritamab) generated approximately USD 333 million in revenue during the first three quarters of 2025.

Amgen continues to be a foundational player in the bispecific antibody space, having pioneered the first FDA-approved bispecific therapy with blinatumomab in 2014. The company further strengthened its position with the approval of Imdelltra (tarlatamab) in 2024 for small cell lung cancer, developed using its proprietary BiTE platform. Johnson & Johnson plays a significant role in the market through its growing hematology franchise, which includes therapies such as Tecvayli (teclistamab) and Blincyto.

Genmab remains a critical innovation engine in the bispecific antibodies ecosystem, primarily through its proprietary DuoBody platform, which enables the development of highly flexible and effective antibody constructs, including those suitable for subcutaneous administration.

Core Growth Drivers

The global bispecific antibody landscape is undergoing rapid and sustained evolution, supported by a growing wave of regulatory approvals that signal strong and rising market demand. This expanding approval base reflects increasing confidence among global health authorities in the safety, efficacy, and therapeutic value of bispecific antibody platforms. As clinical evidence continues to accumulate across multiple disease areas, regulatory agencies are progressively accelerating their evaluation and authorization processes, contributing to broader global adoption of these advanced biologic therapies.

Emerging Opportunity Trends

The clinical pipeline dynamics in the bispecific antibodies market provide important insight into evolving therapeutic priorities and highlight significant opportunities for continued market growth. The distribution of clinical development programs reflects where innovation is most concentrated and which disease areas are receiving the greatest strategic focus from biopharmaceutical developers. As the field matures, the pipeline increasingly demonstrates a structured progression from early-stage experimentation to late-stage validation, signaling a transition toward more commercially viable and clinically established therapies.

Barriers to Optimization

Leukemia and lymphoma continue to pose significant clinical challenges within the bispecific antibodies market due to their complex disease biology and persistent limitations in long-term treatment outcomes. These hematologic malignancies are often characterized by high relapse rates, particularly after initial lines of therapy, which complicates disease management and reduces overall patient survival prospects. Even when patients respond well to first-line treatments, disease recurrence remains common, creating an ongoing need for more durable and effective therapeutic options.

Detailed Market Segmentation

By mechanism of action, immune cell engagers continue to define the primary growth trajectory of the bispecific antibodies market, accounting for approximately 68% of the total share in 2026. This dominance reflects their strong clinical validation and widespread adoption across oncology indications, where harnessing the patient's own immune system has proven to be one of the most effective therapeutic strategies. Within this category, bispecific antibodies are designed to simultaneously bind to immune effector cells and cancer cells, thereby bridging the two and enabling targeted immune-mediated tumor destruction.

By drug, Blinatumomab continues to stand as the commercial cornerstone of the bispecific antibodies sector, accounting for approximately 42% of total market revenue in 2026. Its sustained leadership reflects both its pioneering status as one of the earliest successfully commercialized bispecific T-cell engager therapies and its continued clinical relevance across multiple treatment settings. Over time, it has established a strong competitive position that remains difficult for newer entrants to displace, largely due to its entrenched clinical adoption and extensive real-world usage data.

By indication, hematologic malignancies remain the dominant therapeutic application area for bispecific antibody interventions, accounting for approximately 72% of global market utilization in 2026. This overwhelming share reflects the strong clinical validation and established success of bispecific platforms in targeting blood-based cancers, where disease biology and treatment accessibility are more conducive to precision immunotherapy approaches. Over time, this segment has evolved into the primary clinical stronghold for bispecific development, supported by extensive trial activity and regulatory approvals across multiple regions.

By route of administration, intravenous delivery continues to serve as the primary foundation for bispecific therapy administration, accounting for approximately 58% of the market share in 2025. This sustained dominance reflects the clinical complexity and stringent delivery requirements associated with bispecific antibody treatments, particularly during the early phases of therapy initiation. Despite ongoing advancements in alternative delivery methods, intravenous infusion remains the most widely adopted and trusted approach in both hospital and specialized clinical settings.

Segment Breakdown

By Molecule Format

  • IgG-Like
  • Full-Length IgG
  • Appended-IgG
  • Fragment-Based
  • scFv
  • Fab
  • Fusion / Multispecific

By Technology Platform

  • BiTE
  • CrossMAb
  • DART
  • Knob-into-Hole
  • Other Proprietary

By Mechanism of Action

  • Immune Cell Engagers
  • Payload Delivery
  • Dual Signaling Blockade

By Drug

  • Blinatumomab
  • Tarlatamab
  • Catumaxomab
  • Others

By Indication

  • Hematologic Cancers
  • Solid Tumors
  • Autoimmune & Inflammatory
  • Ophthalmology
  • Others

By Route of Administration

  • Intravenous
  • Subcutaneous

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End User

  • Hospitals
  • Specialty & Cancer Centers
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America continues to dominate the global bispecific antibodies sector, holding an estimated 52% market share as of 2026. This leadership position is largely driven by the strong concentration of advanced biotechnology infrastructure and innovation capacity within the region, particularly in research-intensive economies with well-established pharmaceutical pipelines. The dominance reflects not only commercial scale but also deep scientific capability, regulatory maturity, and sustained investment in next-generation biologics development.
  • At the center of this regional strength is the United States, which anchors the broader North American biopharmaceutical ecosystem. The country hosts a highly developed network of biopharma companies, academic research institutions, and clinical development organizations that collectively accelerate innovation in antibody engineering. Recent industry data indicate that U.S.-based biopharmaceutical firms have invested more than USD 12 billion in antibody engineering and cell-line optimization programs, underscoring the scale of capital allocation toward improving therapeutic precision, manufacturability, and scalability of bispecific antibody platforms.

Leading Market Participants

  • Akeso, Inc
  • Amgen
  • Roche
  • Genentech
  • Janssen
  • Taisho Pharmaceutical
  • Immunocore
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Bispecific Antibodies Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Bispecific Antibodies Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Research & Antibody Engineering / Discovery Platforms
    • 3.1.2. Cell-Line Development & Biologics CDMOs
    • 3.1.3. Bispecific Antibody Developers & Biopharma Manufacturers
    • 3.1.4. Regulatory, Distribution & Specialty Pharmacy Channels
    • 3.1.5. Hospitals, Cancer Centers & Patients
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Bispecific Antibody & Immuno-Oncology Therapeutics Industry
    • 3.2.2. Expanding Approvals and Pipeline Across Hematologic and Solid Tumors
    • 3.2.3. Manufacturing Complexity, CDMO Reliance & Access / Reimbursement Dynamics
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Molecule Format

Chapter 4. Global Bispecific Antibodies Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Bispecific Antibodies Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Molecule Format
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. IgG-Like
          • 5.2.1.1.1.1. Full-Length IgG
          • 5.2.1.1.1.2. Appended-IgG
        • 5.2.1.1.2. Fragment-Based
          • 5.2.1.1.2.1. scFv
          • 5.2.1.1.2.2. Fab
        • 5.2.1.1.3. Fusion / Multispecific
    • 5.2.2. By Technology Platform
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. BiTE
        • 5.2.2.1.2. CrossMAb
        • 5.2.2.1.3. DART
        • 5.2.2.1.4. Knob-into-Hole
        • 5.2.2.1.5. Other Proprietary
    • 5.2.3. By Mechanism of Action
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Immune Cell Engagers
        • 5.2.3.1.2. Payload Delivery
        • 5.2.3.1.3. Dual Signaling Blockade
    • 5.2.4. By Drug
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Blinatumomab
        • 5.2.4.1.2. Tarlatamab
        • 5.2.4.1.3. Catumaxomab
        • 5.2.4.1.4. Others
    • 5.2.5. By Indication
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Hematologic Cancers
        • 5.2.5.1.2. Solid Tumors
        • 5.2.5.1.3. Autoimmune & Inflammatory
        • 5.2.5.1.4. Ophthalmology
        • 5.2.5.1.5. Others
    • 5.2.6. By Route of Administration
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. Intravenous
        • 5.2.6.1.2. Subcutaneous
    • 5.2.7. By Distribution Channel
      • 5.2.7.1. Key Insights
        • 5.2.7.1.1. Hospital Pharmacy
        • 5.2.7.1.2. Retail Pharmacy
        • 5.2.7.1.3. Online Pharmacy
    • 5.2.8. By End User
      • 5.2.8.1. Key Insights
        • 5.2.8.1.1. Hospitals
        • 5.2.8.1.2. Specialty & Cancer Centers
        • 5.2.8.1.3. Others
    • 5.2.9. By Region
      • 5.2.9.1. Key Insights
        • 5.2.9.1.1. North America
          • 5.2.9.1.1.1. The U.S.
          • 5.2.9.1.1.2. Canada
          • 5.2.9.1.1.3. Mexico
        • 5.2.9.1.2. Europe
          • 5.2.9.1.2.1. Western Europe
            • 5.2.9.1.2.1.1. The UK
            • 5.2.9.1.2.1.2. Germany
            • 5.2.9.1.2.1.3. France
            • 5.2.9.1.2.1.4. Italy
            • 5.2.9.1.2.1.5. Spain
            • 5.2.9.1.2.1.6. Rest of Western Europe
          • 5.2.9.1.2.2. Eastern Europe
            • 5.2.9.1.2.2.1. Poland
            • 5.2.9.1.2.2.2. Russia
            • 5.2.9.1.2.2.3. Rest of Eastern Europe
        • 5.2.9.1.3. Asia Pacific
          • 5.2.9.1.3.1. China
          • 5.2.9.1.3.2. India
          • 5.2.9.1.3.3. Japan
          • 5.2.9.1.3.4. Australia & New Zealand
          • 5.2.9.1.3.5. South Korea
          • 5.2.9.1.3.6. ASEAN
          • 5.2.9.1.3.7. Rest of Asia Pacific
        • 5.2.9.1.4. Middle East & Africa (MEA)
          • 5.2.9.1.4.1. Saudi Arabia
          • 5.2.9.1.4.2. South Africa
          • 5.2.9.1.4.3. UAE
          • 5.2.9.1.4.4. Rest of MEA
        • 5.2.9.1.5. South America
          • 5.2.9.1.5.1. Argentina
          • 5.2.9.1.5.2. Brazil
          • 5.2.9.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Molecule Format
      • 6.2.1.2. By Technology Platform
      • 6.2.1.3. By Mechanism of Action
      • 6.2.1.4. By Drug
      • 6.2.1.5. By Indication
      • 6.2.1.6. By Route of Administration
      • 6.2.1.7. By Distribution Channel
      • 6.2.1.8. By End User
      • 6.2.1.9. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Molecule Format
      • 7.2.1.2. By Technology Platform
      • 7.2.1.3. By Mechanism of Action
      • 7.2.1.4. By Drug
      • 7.2.1.5. By Indication
      • 7.2.1.6. By Route of Administration
      • 7.2.1.7. By Distribution Channel
      • 7.2.1.8. By End User
      • 7.2.1.9. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Molecule Format
      • 8.2.1.2. By Technology Platform
      • 8.2.1.3. By Mechanism of Action
      • 8.2.1.4. By Drug
      • 8.2.1.5. By Indication
      • 8.2.1.6. By Route of Administration
      • 8.2.1.7. By Distribution Channel
      • 8.2.1.8. By End User
      • 8.2.1.9. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Molecule Format
      • 9.2.1.2. By Technology Platform
      • 9.2.1.3. By Mechanism of Action
      • 9.2.1.4. By Drug
      • 9.2.1.5. By Indication
      • 9.2.1.6. By Route of Administration
      • 9.2.1.7. By Distribution Channel
      • 9.2.1.8. By End User
      • 9.2.1.9. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Molecule Format
      • 10.2.1.2. By Technology Platform
      • 10.2.1.3. By Mechanism of Action
      • 10.2.1.4. By Drug
      • 10.2.1.5. By Indication
      • 10.2.1.6. By Route of Administration
      • 10.2.1.7. By Distribution Channel
      • 10.2.1.8. By End User
      • 10.2.1.9. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Akeso, Inc
  • 11.2. Amgen
  • 11.3. Roche
  • 11.4. Genentech
  • 11.5. Janssen
  • 11.6. Taisho Pharmaceutical
  • 11.7. Immunocore
  • 11.8. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators